Johnson & Johnson JNJ.SW · Stock Open Johnson & Johnson in new tab
Johnson & Johnson Analysis (JNJ.SW)
Is Johnson & Johnson a good investment? Johnson & Johnson (JNJ.SW) is currently trading at 193.57 CHF.
In terms of valuation, the stock trades at a P/E ratio of 22.59. This valuation is generally in line with the broader market.
Earnings Schedule: Johnson & Johnson is expected to release its next earnings report on July 22, 2026.
For income investors, Johnson & Johnson pays a dividend yield of 2.13%.
Investor FAQ
Does Johnson & Johnson pay a dividend?
Yes, it pays an annual dividend of 4.05 CHF (2.13% yield).
What asset class is Johnson & Johnson?
Johnson & Johnson is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be July 22, 2026. The company currently has a trailing EPS of 8.57.
Company Profile
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
| Year | Total Dividends |
|---|---|
| ▸2027 |
1.03 CHF
|
| March 9, 2027 (estimated) | 1.0327 |
| ▸2026 |
4.19 CHF
|
| Dec. 8, 2026 (estimated) | 1.0742 |
| Sept. 8, 2026 (estimated) | 1.0568 |
| June 9, 2026 | 1.0517 |
| March 10, 2026 | 1.0066 |
| ▸2025 |
4.29 CHF
|
| Dec. 9, 2025 | 1.0503 |
| Sept. 9, 2025 | 1.0458 |
| June 10, 2025 | 1.0779 |
| March 4, 2025 | 1.1205 |
| ▸2024 |
4.32 CHF
|
| Dec. 10, 2024 | 1.0995 |
| Sept. 10, 2024 | 1.0443 |
| June 4, 2024 | 1.1299 |
| March 5, 2024 | 1.0488 |
| ▸2023 |
4.22 CHF
|
| Dec. 5, 2023 | 1.0535 |
| Sept. 7, 2023 | 1.0527 |
| June 6, 2023 | 1.0698 |
| March 7, 2023 | 1.0448 |
| ▸2022 |
4.24 CHF
|
| Dec. 6, 2022 | 1.0839 |
| Sept. 6, 2022 | 1.0897 |
| June 7, 2022 | 1.0931 |
| March 8, 2022 | 0.9773 |
| ▸2021 |
3.92 CHF
|
| Dec. 7, 2021 | 0.9894 |
| Sept. 7, 2021 | 0.9679 |
| June 8, 2021 | 0.9501 |
| March 9, 2021 | 1.0100 |
| ▸2020 |
3.98 CHF
|
| Dec. 8, 2020 | 1.0100 |
| Sept. 8, 2020 | 1.0100 |
| June 9, 2020 | 1.0100 |
| March 10, 2020 | 0.9500 |
| ▸2019 |
3.75 CHF
|
| Dec. 10, 2019 | 0.9500 |
| Sept. 10, 2019 | 0.9500 |
| June 11, 2019 | 0.9500 |
| March 12, 2019 | 0.9000 |
| ▸2018 |
3.54 CHF
|
| Dec. 11, 2018 | 0.9000 |
| Sept. 11, 2018 | 0.9000 |
| June 12, 2018 | 0.9000 |
| March 13, 2018 | 0.8400 |
| ▸2017 |
3.32 CHF
|
| Dec. 12, 2017 | 0.8400 |
| Sept. 12, 2017 | 0.8400 |
| June 13, 2017 | 0.8400 |
| March 14, 2017 | 0.8000 |
| ▸2016 |
3.15 CHF
|
| Dec. 6, 2016 | 0.8000 |
| Sept. 6, 2016 | 0.8000 |
| June 7, 2016 | 0.8000 |
| March 8, 2016 | 0.7500 |
| ▸2015 |
2.95 CHF
|
| Dec. 8, 2015 | 0.7500 |
| Sept. 8, 2015 | 0.7500 |
| June 9, 2015 | 0.7500 |
| March 10, 2015 | 0.7000 |
| ▸2014 |
2.76 CHF
|
| Nov. 21, 2014 | 0.7000 |
| Aug. 22, 2014 | 0.7000 |
| May 22, 2014 | 0.7000 |
| Feb. 21, 2014 | 0.6600 |
| ▸2013 |
2.59 CHF
|
| Nov. 22, 2013 | 0.6600 |
| Aug. 23, 2013 | 0.6600 |
| May 23, 2013 | 0.6600 |
| Feb. 22, 2013 | 0.6100 |
| ▸2012 |
2.40 CHF
|
| Nov. 23, 2012 | 0.6100 |
| Aug. 24, 2012 | 0.6100 |
| May 24, 2012 | 0.6100 |
| Feb. 24, 2012 | 0.5700 |
| ▸2011 |
2.25 CHF
|
| Nov. 25, 2011 | 0.5700 |
| Aug. 26, 2011 | 0.5700 |
| May 26, 2011 | 0.5700 |
| Feb. 25, 2011 | 0.5400 |
| ▸2010 |
2.11 CHF
|
| Nov. 26, 2010 | 0.5400 |
| Aug. 27, 2010 | 0.5400 |
| May 27, 2010 | 0.5400 |
| Feb. 19, 2010 | 0.4900 |
| ▸2009 |
1.93 CHF
|
| Nov. 20, 2009 | 0.4900 |
| Aug. 21, 2009 | 0.4900 |
| May 20, 2009 | 0.4900 |
| Feb. 20, 2009 | 0.4600 |
| ▸2008 |
1.80 CHF
|
| Nov. 21, 2008 | 0.4600 |
| Aug. 22, 2008 | 0.4600 |
| May 22, 2008 | 0.4600 |
| Feb. 22, 2008 | 0.4150 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Johnson & Johnson | Jun 09, 2026 | Paid | 1.0517 CHF |
| Johnson & Johnson | Mar 10, 2026 | Paid | 1.00658 CHF |
| Johnson & Johnson | Dec 09, 2025 | Paid | 1.05034 CHF |
| Johnson & Johnson | Sep 09, 2025 | Paid | 1.04577 CHF |
Community Discussion